Up to now, Mindray's products and solutions have been applied to more than 190 countries around the world, covering nearly 110,000 medical institutions in China and more than 95% of the top three hospitals. It is known as the “China Huawei†in the medical industry.
First, the product elements:
Second, the overview of investment targets
1. Mind's product share:
Remarks: The above is the global market share of Mindray Medical's products. The above is basically the number one consecutive domestic ranking.
2. Financial data and forecasts:
Note: 15 years net profit reduction instructions
1. Preparation for delisting from the United States and exercise of equity incentive plan;
2. At the end of the year, the internal sales and management system will be fully integrated to improve the efficiency of sales operations; the R&D management system at home and abroad will be integrated, redundant personnel and institutions will be tailored, and R&D efficiency and management costs will be reduced.
3. Mindray Medical Listing Planning Steps:
1) Complete the equity change at the end of 2016;
2) Start the backdoor negotiation at the end of 2016;
3) Submit the listing materials in the first quarter of 2017;
The IPO and the backdoor are implemented synchronously, which one is quick to choose.
Shanghai J.Shine Co.,Ltd , https://www.jshinechem.com